You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 298 No. 22, December 12, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Arrhythmias
 •Drug Therapy
 •Adverse Effects
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Use of Amiodarone

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Clinical Review, Drs Vassallo and Trohman1 examined the role of amiodarone in different clinical settings and, in particular, suggested that "amiodarone can be used safely in patients with left ventricular dysfunction and CHF [congestive heart failure]." However, the authors did not provide a complete analysis of the relevant clinical trials.

In the GESICA trial,2 amiodarone reduced mortality, but that study was conducted in a single country, so its results may not be applicable to a broader spectrum of populations with a diverse natural history of CHF. In addition, GESICA had not been blinded. This shortcoming, along with the observation of an unexpectedly low drop-out rate (3%) despite amiodarone's well-known toxicity, suggest that the results should be viewed with caution.

The CHF-STAT study3 was placebo-controlled but had other limitations that could have affected the purported neutral effect on survival: small patient population, limited follow-up, and lack . . . [Full Text of this Article]

Michele Coceani, MD
michecoc@ifc.cnr.it
CNR Institute of Clinical Physiology
Pisa, Italy



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTERS

Use of Amiodarone
John R. Kapoor
JAMA. 2007;298(22):2617.
EXTRACT | FULL TEXT  

Use of Amiodarone—Reply
Patricia Vassallo and Richard G. Trohman
JAMA. 2007;298(22):2618.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
Patricia Vassallo and Richard G. Trohman
JAMA. 2007;298(11):1312-1322.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.